Meet our team

<p><em>“The ‘incredible’ Dominic Adair is a clear leader in patent litigation, with peers admiring his wealth of knowledge, particularly when it comes to the biotechnology and pharmaceutical sectors.” </em>(Who’s Who Legal 2023)</p> <p>In the pharmaceutical and biotechnology sector, Dominic has worked on all aspects of the drug life cycle, from freedom to operate analyses and early-stage risk assessment of generic competition to complex end-stage litigation, SPCs and anti-trust issues. A technical background in the life sciences makes Dominic comfortable handling the most complex disputes in this area. His cases have required him to spend years on the scientific concepts underlying some of the most valuable patents in the world, including deprotection reactions in the synthesis of acyl compounds and the regulation of immune checkpoint inhibitors. But his experience of technology is truly varied, including computer hardware, electronic control systems, petrochemical and mechanical engineering and consumer products, including triple-blade razors, bag-in-bottle beer kegs and reduced-harm cigarette filters.</p> <p>Dominic has handled cases across the range of tribunals in the UK and the EPO and has coordinated litigation across Europe and the world. This coordination work, for both rights holders and defendants, has been a mainstay of Dominic’s practice for 20 years, enabling to develop the broadest possible outlook on strategy and a comprehensive tactical playbook. A natural team player, he has assisted clients in bringing patent cases all across the world, from the constitutional courts of Mexico to the Supreme Court of India.</p> <p>Representative UK cases include:</p> <ul> <li>Celltrion v Biogen, Roche & Genentech – revocation action in the Patents Court in relation to biosimilar rituximab product.</li> <li>Gillette v Wilkinson Sword – defence of infringement claim in the Patents Court and counterclaim for revocation of Gillette patent relating to connectors for triple-blade razor cartridges.</li> <li>Heineken v Anheuser-Busch Inbev – revocation claim in the Patents Court against ABI patents relating to bag-in-bottle dispensing technology and defence of infringement counterclaim.</li> <li>Innovia v Frito-Lay – entitlement dispute and breach of confidence action in the Patents Court including jurisdiction challenge involving the Eastern District of Texas.</li> <li>Merck Serono v AbbVie – revocation action in the Patents Court in relation to biosimilar adalimumab product.</li> <li>Novartis v Actavis – preliminary injunction proceedings and infringement claim in the Patents Court concerning the scope of the SPC for valsartan (Diovan®) in relation to combination products.</li> <li>Scientific Drilling v Gyrodata – revocation claim in the Patents Court against Gyrodata patents for methods of measuring tortuosity in oil well boreholes.</li> <li>Secretary of State for Health v Servier – defence of £200m damages claim brought by the UK Government for alleged breaches of competition law, including alleged abuse of dominant position by maintaining a patent for perindopril (Coversyl®) that was later held invalid.</li> <li>Tehrani v Hamilton – defence of infringement claim in the IPEC and counterclaim for revocation of Tehrani patent relating to electronic control systems for hospital ventilators.</li> <li>Truck-Align v Deans Systems – defence of infringement claim in the Patents Court and counterclaim for revocation of Truck-Align patent relating to manually-operated ramp assemblies.</li> <li>Whitaker Corp v FCI – defence of infringement claim in the Patents Court and counterclaim for revocation of Whitaker patent relating to impedance-matched backplane connectors for printed circuit boards.</li> </ul> <p>Representative coordination projects include:</p> <ul> <li>Assisting a large Swiss pharma company coordinate litigation on the patents involved in several projects, including: <ul> <li>Its top-selling hypertension drug across 128 countries</li> <li>Its combination therapy hypertension product across 77 countries</li> <li>Its top-3 product for the treatment of blood diseases across 32 countries</li> </ul> </li> <li>Assisting a medium-sized Swiss pharma company coordinate litigation on the patents surrounding its top-selling anaemia treatment, a non-biological complex drug, across Europe.</li> <li>Assisting a large Korean biosimilar maker coordinate defensive litigation during the launch of two antibody products across Europe.</li> </ul> <p>Dominic writes regularly on reported patent cases in the UK, EPO and UPC and is editor of Bristows’ annual review of patent cases. For several years he co-chaired C5’s Pharma and Biotech Patent Litigation Conference in Amsterdam and remains a regular conference attendee and presenter.</p> <p>Dominic is a member of CIPA, EPLAW and AIPPI and holds office as the Honorary Secretary and Vice-President of AIPPI UK. He also sits on the Membership Committee of AIPPI at the international level.</p>

<p><em>“Tim is a fantastic real estate lawyer. He is commercially astute and is well versed in dealing with occupiers across multiple sectors and geographies.”</em> (Chambers and Partners 2024)</p> <p>Tim heads up Bristows’ real estate practice and has strong expertise in complex asset management, build to rent and corporate occupier work across a range of sectors including legal, logistics and financial services. He advises a major UK healthcare provider on their real estate portfolio and recently led the real estate aspects of a £1.1bn sale and leaseback transaction.</p> <p>Tim specialises in commercial real estate with extensive experience of BTR development projects, sale and leaseback deals, asset management and complex corporate occupier deals. Some of Tim’s work highlights include:</p> <ul> <li>Advising one of the UK’s largest healthcare providers on the real estate aspects of a £1.1bn sale and leaseback transaction.</li> <li>Advising a US based global law firm on the acquisition of a new European headquarters in the City of London.</li> <li>Advising a build to rent developer on the conditional purchase of an office block from a sovereign wealth fund.</li> <li>Advising a build to rent developer on site assembly and conditional purchase of a proposed development site with an anticipate GDV of £650m.</li> <li>Advising on the sale of a UK consulate.</li> <li>Advising an overseas landlord client on the re-structuring of management arrangements for a landmark central London asset.</li> </ul> <p>Tim is interested in the potential for technology to improve the way that property is designed, constructed, traded and occupied.</p> <p>Tim has committed to promoting London as a home for the international technology community as a Tech London Advocate.</p>

<p>Greg’s extensive scientific background gives him a valuable understanding of technical issues that can underlie IP matters, particularly in the life sciences field. For almost 20 years, he has advised and represented clients on small molecule pharmaceuticals, biologics (originators and biosimilars), biomanufacturing, medical devices (hardware and software), as well as in the chemicals, cosmetics, food, shipping and online publishing sectors.</p> <p>Greg has represented clients in many patent cases before both the English High Court (including Patents Court) and Court of Appeal. In addition, Greg has extensive experience of strategic multinational litigation in multiple jurisdictions, including at the EPO, through global pharmaceutical product coordination projects for many clients. He is also an Authorised Representative handling cases before the UPC.</p> <ul> <li>In the UPC, Greg was part of team of internationally recognised lawyers that represented <strong>Novartis</strong> in the defence of a DNI action instigated in the Central Division (Milan) by Accord in relation to patents to Tasigna® (nilotinib).</li> <li><strong>Winnow</strong> v Orbisk – representing patentee Winnow in UPC proceedings before the Local Division (The Hague) concerning commercial food waste management solutions.</li> <li>DSM v <strong>Mara Renewables & Algal Omega 3</strong> – Patents Court litigation concerning omega-3 microbial oils, and processes for their manufacture. Mara successfully revoked 2 of the 3 patents in suit, clearing the way to continue manufacture and sale of its products.</li> <li><strong>Novartis</strong> v Teva & Ors – Patents Court and Court of Appeal litigation concerning dosage regime patent for client’s blockbuster fingolimod product (Gilenya®), including ground-breaking application for interim injunctive relief pre-patent grant and significant decisions on the availability of Arrow declarations for use in foreign proceedings.</li> <li>Otsuka v <strong>GW Pharma</strong> – IP licence dispute relating to client’s Epidiolex®/Epidyolex® cannabidiol (CBD) treatment for epilepsy.</li> <li>Lilly v <strong>Novartis;</strong> UCB v <strong>Novartis</strong> – acting for Novartis in relation to global enforcement of IL-17AF antibody patent portfolio against IL-17 antibody products Taltz® and Bimzelx®.</li> <li>Parainen Pearl Shipping v <strong>Kristian Gerhard Jebsen Skipsrederi</strong> – case on exhaustion of patent rights in a pneumatic cement discharge system for a ship, including a pan-European jurisdiction challenge.</li> <li><strong>Novartis</strong> v Focus, Actavis & Teva – Patents Court and Court of Appeal patent litigation concerning transdermal dosage regime patent for rivastigmine (Exelon®), including global coordination of parallel litigation and EPO opposition.</li> <li>Orion v SS for Health and Social Care & <strong>Ever Neuro</strong> – judicial review challenge to decision of MHRA to grant generic marketing authorisation for dexmedetomidine hydrochloride, involving question of whether pre-accession Czech MA was compatible with Directive 2001/83/EC and thus the first MA for the purposes of calculating the term of data exclusivity.</li> <li><strong>Celltrion</strong> v Biogen, Roche & Genentech – clearing the way revocation action in the Patents Court in relation to biosimilar rituximab product (MabThera®).</li> <li><strong>Merck Serono</strong> v AbbVie – clearing the way revocation action in the Patents Court in relation to biosimilar adalimumab product (Humira®).</li> <li>ConvaTec v <strong>Smith & Nephew</strong> – long-running case in the Patents Court and Court of Appeal concerning patents and claims to misuse of confidential information in relation to gel-forming wound dressings (Durafiber®), and subsequent damages claim under a cross-undertaking.</li> <li>Allergan v <strong>Ipsen</strong> – patent litigation in the Patents Court on second medical use patents to botulinum toxin (Dysport®).</li> <li><strong>Servier</strong> v National Institute of Health and Clinical Excellence (NICE) – successful judicial review of NICE decision not to recommend a client’s osteoporosis treatment (Protelos®).</li> </ul> <p>He has also spent time on secondment to the IP litigation department of a leading IP law firm in the Netherlands as well as the UK legal department of a global healthcare IT company, working on non-contentious IP/IT, regulatory and commercial matters.</p> <p>Greg is a member of AIPPI (Association for Protection of Intellectual Property) and EPLAW (European Patent Lawyers Association), and is a regular speaker at international conferences on UK and international patent litigation, including the UPC.</p>

<p>Jeremy is a leading trade mark, <a href="/expertise/litigation-dispute-resolution/brands-designs-copyright/">copyright and design</a> litigator and is described as “an incredible practitioner and a brilliant litigation strategist”. He regularly leads large teams in high value IP litigation. Jeremy’s practice covers clients who are household names in all sectors ranging from luxury goods, <a href="/expertise/sectors/technology/">technology</a>, pharmaceuticals, consumer goods and professional services.</p> <p>Jeremy has acted in some of the leading cases that have developed intellectual property law such as:</p> <ul> <li>L’Oreal v eBay which concerned the liability of online e-commerce platforms and was the first case to consider injunctions against non-infringing intermediaries.</li> <li>Cadbury v Nestle which concerned the registrability of the shape of a four fingered KitKat chocolate bar.</li> <li>Glaxo v Sandoz concerning the colour and shape of an asthma inhaler for passing off.</li> <li>Swatch v Samsung (Court of Appeal) where Jeremy acted as co-counsel in the appeal relating to the scope of the e-Commerce Defence for a platform.</li> </ul> <p>Though many of his clients are claimants, Jeremy has been part of the team that has made Bristows one of the UK’s leading IP defence firms having defended Vectura, Fidelis, Verweij Fashion, YouView and BDO Unibank in full trials before the High Court.</p> <p>More recently Jeremy has acted for:</p> <ul> <li>Newmark (part of Cantor Fitzgerald) in a novel declaration of non-passing off action to ensure continued use of the name in the UK which was stayed shortly before a 12 day trial (Claim IP- 2022-0000115).</li> <li>Delvaux, the luxury leather goods company in a passing off claim against Longchamp (Claim IP- 2023- 000098).</li> <li>Glebe Farm in the widely publicised trade mark infringement and passing off claim brought by Oatly AB.</li> <li>Muzmatch in the widely publicised trade mark infringement and passing off claim brought by Match.com.</li> <li>Heineken in a claim relating to an alcohol free beer.</li> </ul> <p>Jeremy has extensive experience in seeking or defending interim relief applications and has successfully obtained interim injunctions, seizure orders and Norwich Pharmacal orders (requiring a third party to disclose details of an alleged infringer) for luxury goods clients.</p> <p>Jeremy also has extensive registered design, unregistered design and copyright litigation experience for a diverse range of products ranging from tech services, luxury jewellery and fashion, pharmaceutical products and consumer goods.</p> <p>From acting in cases about the liability of platforms, Jeremy has a specialism in strategies to combat IP infringement in the digital world as well as advising about the potential liability of technology platforms.</p> <p>Jeremy was past Chair of the MARQUES Dispute Resolution committee and is a member of various INTA committees.</p>

<p>James specialises in patent litigation. He is “technically very insightful” (Chambers 2024) and leaves “a very positive impact” on clients (JUVE 2024).</p> <p>James’ doctorate in optoelectronics and general background in physics provides him with a firm understanding of highly technical issues. He is experienced in working with a diverse range of technical subject matter from mobile telecommunications, human computer interaction, and data storage to immunoassay techniques and pharmaceuticals. He has been at the cutting edge of standard essential patent and FRAND disputes for more than 20 years. His work in this field has spanned four generations of telecommunications technology: 2G, 3G, 4G and 5G, and has led to successful outcomes for both SEP holders and implementers.</p> <p>James was closely involved with preparations for the UPC and led a team in our well publicised UPC Moot designed to stress test the UPC procedures in a real-time framework. He has recently been involved in co-ordinating proceedings across the US, UK, Germany and the UPC.</p> <p>The cases below illustrate James’ impressive track record in achieving positive outcomes for his clients by commercial settlement or judgment of the court.</p> <ul> <li>Texas Instruments v Network System Technologies – acting for Texas Instruments in the revocation of patents relating to network-on-a-chip technology. Co-ordinating with proceedings brought by NST in the UPC on the same patent families.</li> <li>Philips v ASUS and HTC, Philips v TCL, Philips v Xiaomi, and Philips v Oppo – acting for Philips in a series of separate patent infringement claims on standard essential telecommunications technology (3G, 4G and 5G) and FRAND related issues. Successfully defending a preliminary pass-through licence issue; upholding two standard essential telecommunications patents as valid and infringed; defending jurisdiction challenges, and obtaining anti-anti suit relief. Cross-examining the other side’s expert witness in Philips v Xiaomi. Co-ordinating with proceedings in Germany, the Netherlands, France and India. In each case, proceedings settled shortly before the FRAND determination.</li> <li>Unwired Planet v Huawei, Samsung and Google – acting for Samsung and Google on patent infringement claims for standard essential, and non-essential, telecommunications patents and FRAND issues. Both Samsung and Google settled prior to the FRAND determination.</li> <li>IPCom v HTC – acting for IPCom on standard essential patent infringement claims and FRAND issues. Successfully upholding a standard essential patent on random access as valid and infringed.</li> <li>EMGS v PGS – defending a patent infringement claim relating to electromagnetic survey techniques for oil and gas. Acting as co-counsel in parallel Norwegian proceedings, cross examining technical witnesses in the Oslo City Court and successfully invalidating the patent. The dispute settled following the trial in the English Patents Court, but prior to judgment.</li> <li>Philips v Nintendo – acting for Philips in its successful claim for patent infringement on human computer interaction and computer vision technology relating to the Wii remote.</li> <li>Philips v Garmin – acting for Philips on wearable fitness tracking technology. Defending a revocation claim on the amended form of the patent and successfully bringing an infringement counterclaim.</li> <li>Pratt & Whitney v Rolls Royce – acting for Pratt & Whitney in patent infringement proceedings on swept fan blade technology. The dispute settled prior to trial in the Patents Court.</li> <li>Aerotel v Telco – acting for Aerotel in relation to a patent infringement claim relating to a telecommunication system. Successful on appeal: reversing a first instance summary judgment decision on the grounds of lack of patentability, establishing the Aerotel test used for patentability of computer related inventions.</li> <li>Affymetrix v Multilyte – acting for Affymetrix in the successful revocation of immunoassay patents held by Multilyte.</li> </ul> <p>James has taken on the role of advocate in the English Patents Court and in the Norwegian Oslo City Court. In addition to patent and FRAND issues, his work on standard essential patents has involved contractual disputes, issues of foreign law, jurisdiction challenges and anti-suit relief. He has successfully defended multiple jurisdiction challenges and obtained pre-emptive anti-anti suit relief on an ex parte basis. He is experienced in coordinating parallel litigation in Europe, North America and Asia.</p> <p>James is a qualified Solicitor-Advocate with full rights of audience before all of the UK’s civil courts. He is a member of AIPPI and CIPA. James is part of the Mindful Business Charter taskforce that drafted the MBC guidance on the conduct of litigation and dispute resolution.</p>

<p>Xisca is a dual-qualified lawyer in England & Wales and Spain who specialises in all aspects of EU and UK regulatory law in the biopharmaceutical and medical technologies sectors.</p> <p>Xisca advises on a broad range of regulatory law topics including: regulatory strategies for bringing products to market, product life cycle management, regulatory exclusivities, clinical trials and non-interventional trials, including the implementation of the Clinical Trial Regulation, orphan medicinal products, obligations and rewards in relation to paediatric research including agreeing and modifying PIPs, waivers and deferrals and compliance with agreed PIPs, and parallel trade of medicines. She also advises on the regulatory framework applicable to medical devices and in vitro diagnostics.</p> <p>Xisca has broad experience in manufacturing and distribution issues, including supply management policies, product shortages and recalls, and compliance with GMP, GDP and labelling requirements. She has supported GCP and GMP inspections, both at national and EU level.</p> <p>She also advises life sciences companies on the consequences of Brexit, including changes required to ensure business continuity further to the UK’s withdrawal from the EU.</p> <p>Previously she was an in-house lawyer at a leading innovative biopharmaceutical company, where she provided regulatory law support to all business units and functions at EU and global level, gaining excellent knowledge of the pharmaceutical industry enabling her to bring a strong business approach to her legal advice. Prior to that, she was an associate in the IP litigation team at a magic circle law firm in Barcelona for almost 10 years.</p>

<p><em>“Andrew Bowler is great to work with. He is very smart and combines a comprehensive understanding of the case detail with an impressive strategic awareness. His judgement and advice on matters of strategy are invariably spot on.” (</em>Legal 500 2025<em>)</em></p> <p>Andy is joint head of the patent litigation department.</p> <p>Andy has considerable experience of representing high profile clients in patent disputes across a wide range of technologies, including complex mechanical and FMCG products, pharmaceuticals, mobile phones (including FRAND), automotives, electronics and medical devices. He has conducted several successful mediations of patent disputes and regularly provides freedom to operate and validity opinions. He is frequently asked by clients to coordinate cross-border litigation around the World.</p> <p>Andy has acted in many leading cases over recent years, including:</p> <ul> <li>Conversant v ZTE in the High Court, Court of Appeal and Supreme Court (acting for ZTE).</li> <li>Teva v Bayer in the High Court and Court of Appeal (acting for Teva).</li> <li>Siemens Gamesa v GE; GE v Siemens Gamesa in the High Court (acting for Siemens Gamesa).</li> <li>Unwired Planet v Samsung in the High Court (acting for Samsung).</li> <li>Heineken v Anheuser–Busch (acting for Heineken).</li> <li>Wobben v Siemens Wind Power in the High Court and Court of Appeal (acting for Siemens).</li> <li>Sandvik v Kennametal in the High Court (acting for Kennametal).</li> <li>Jushi v OCV in the Court of Appeal (acting for Jushi).</li> <li>Alcon Pharmaceuticals v Pharmathen in the High Court (acting for Alcon).</li> <li>Allergan v Ipsen (acting for Ipsen).</li> <li>BAE v Thales (acting for Thales).</li> <li>Siemens v Seagate in the Belfast High Court (acting for Siemens).</li> </ul> <p>Andy has experience of making discovery applications to UK courts pursuant to letters of request/letters rogatory issued by foreign courts. He also has an interest in cases involving misappropriation of trade secrets, and in arbitrations.</p> <p>Andy is frequently asked to comment and lecture on IP issues and is a regular speaker at international conferences on strategic considerations for European and international patent litigation. He regularly provides comments to the national press on intellectual property issues. He is on the Lexis Nexis IP & IT Editorial Board.</p>

<p>Mark has approaching 30 years’ experience handling complex contract and tort disputes at all levels of the English courts and in ad hoc and institutional arbitrations.</p> <p>Mark’s clients include corporations operating in industry sectors including <a href="https://www.bristows.com/expertise/sectors/life-sciences/">life sciences</a>/pharma, information <a href="https://www.bristows.com/expertise/sectors/technology/">technology</a> and digital media. He is highly experienced in both court litigation and arbitration, as well as managing and resolving commercial disputes before they reach court or an arbitral tribunal.</p> <p>Mark’s disputes expertise in the life sciences sector runs across a variety of sector-specific contracts relating to IP-rich assets and highly technical subject matter, ranging from licences and collaboration agreements to supply and distribution contracts. He also experienced in product liability and misuse of confidential information disputes. His clients include several household name pharmaceutical companies.</p> <p>Mark’s life sciences experience includes:</p> <ul> <li>Representing a pharma company in a licence royalties claim for the development of a monoclonal antibody blockbuster drug.</li> <li>Acting for a pharma company in a contested termination of a contract for the manufacture and supply of a licensed active pharmaceutical ingredient and failure to comply with “reasonable endeavours” obligations under a licence, development and commercialisation contract.</li> <li>Representing a pharma company in a claim against a CMO for breaches of a technical quality agreement and GMP guidelines for out-of-specification API batches.</li> <li>Advising a biotech company concerning breaches of work orders under a master services agreement for the conduct of clinical trials.</li> <li>Acting for a pharma company in a claim of misuse of confidential information relating to the formula of an active pharmaceutical ingredient.</li> </ul> <p>Mark’s tech, media and telecoms experience includes:</p> <ul> <li>Representing global advertising and media company, WPP, in a dispute over breaches of a share purchase agreement concerning a cutting-edge programmatic platform placing £billions worth of digital advertising annually.</li> <li>Representing the UK’s telecoms regulator Ofcom to enforce regulatory fines for breaches of the Broadcasting Code.</li> <li>Acting for leading gaming developer/publisher, Activision Blizzard, in obtaining first English court injunction restraining the use of “cheats” and “bots” in the digital gaming environment.</li> <li>Acting for leading telecoms and cloud communications company in a wrongful termination contract dispute with the principal Algerian mobile network operator relating to an MSA for connecting international application-to-person messaging.</li> </ul> <p>Mark runs Bristows’ Groupe Juridique Francophone, which provides a full range of legal services to French and Francophone companies with commercial interests in the UK. He speaks fluent French and Italian.</p> <p>Mark is a member of The Association for International Arbitration.</p>

<p>Rob is joint head of the patent litigation department. He has a PhD in molecular genetics, over 20 years of litigation experience, and is particularly active on litigation matters for clients within the life sciences sector.</p> <p>Such matters often require the coordination of parallel proceedings in the UK, EPO and other jurisdictions within Europe (including at the UPC) and elsewhere in the world. He therefore has in-depth knowledge of European litigation and, alongside appearing for clients in the High Court and Court of Appeal, has attended preliminary injunction and main action proceedings in multiple countries within Europe and overseen inspections of pharmaceutical manufacturing processes in India and Japan. Rob also has first-hand experience of SPC proceedings before the Court of Justice of the European Union.</p> <p>Rob’s leading cases include:</p> <ul> <li><strong>Teva v Bayer</strong> – Revocation proceedings in the UK, and coordination of parallel proceedings across Europe, in respect of patents for a cancer treatment.</li> <li><strong>Teva</strong> <strong>v Janssen</strong> – Defence of SPC revocation proceedings in the UK in respect of Arts 3(c) and 3(d) SPC Regulation and a treatment for schizophrenia.</li> <li><strong>Regeneron & Teva v Rinat </strong>– Revocation proceedings in the UK (and the EPO) in respect of patents for antibodies for the treatment of osteoarthritis.</li> <li><strong>GSK v Vectura</strong> – Defence of patent revocation proceedings and Arrow declaratory relief in respect of drug particles for inhalation formulations.</li> <li><strong>Sandoz v Searle (Janssen) </strong>– Defence of SPC revocation proceedings in respect of Art 3(a) SPC Regulation and a treatment for HIV. Includes a reference from the Court of Appeal to the CJEU.</li> <li><strong>Merck Sharp & Dohme v Shionogi – </strong>Defence of patent revocation proceedings in respect of Markush claims and a treatment for HIV.</li> <li><strong>Generics (UK) v Novartis</strong> – Defence of patent and SPC revocation proceedings in the UK, and coordination of parallel proceedings across Europe, in respect of a treatment for Alzheimer’s disease.</li> <li><strong>Actavis v Novartis </strong>– Defence of patent revocation proceedings in the UK, and coordination of parallel proceedings across Europe, in respect of a formulation patent for a cholesterol-reducing agent.</li> <li><strong>AstraZeneca v Krka </strong>– Damages enquiry following preliminary injunction and patent infringement proceedings.</li> <li><strong>Lundbeck v Lagap </strong>– Defence of patent infringement proceedings. Included inspection of pharmaceutical production process in India.</li> </ul> <p>Alongside his patent litigation practice, Rob also advises on other IP rights and is one of a small number of lawyers who have acted in matters concerning plant variety rights – such experience extends to enforcement, contractual disputes and compulsory licensing. In addition, Rob regularly assists clients with freedom to operate opinions and due diligence on the intellectual property aspects of commercial transactions.</p> <p>Rob is one of the founding editors of Bristows’ Biotech Review publication.</p> <p>Rob is a member of EPLAW, CIPA and a regular participant at the IPLA.</p>

<p>Miranda is a corporate tax specialist with over 30 years’ experience. She advises clients from early stage tech and life sciences companies to multi-national corporations operating in the pharma, tech and consumer products industries on the whole gamut of tax issues that they face in carrying on their businesses.</p> <p>Specialist areas include:</p> <ul> <li>Advising businesses, both UK-based and overseas, on the structure and negotiation of M&A deals and other forms of corporate/commercial transaction such as joint ventures, financings, capital raisings, reorganisations, and IP contracts/licensing arrangements.</li> <li>Advising on employee tax issues and share incentives, particularly enterprise management incentives and other option schemes for growing companies.</li> <li>General VAT advice.</li> <li>Advising on the full range of tax issues affecting clients in the charities and not-for-profit sector.</li> </ul> <p>Some of Miranda’s recent work highlights include:</p> <ul> <li>Advising a multinational communications company on various acquisitions including the acquisition of a marketing solutions company.</li> <li>Advising a fibre network provider on the divestment of one of its subsidiaries.</li> <li>Advising a global marketing services company on various strategic acquisitions.</li> <li>Advising a Spanish biotech company on its UK operations and employee incentives.</li> <li>Advising on the sale of a TV production and event staging company to a large multinational entertainment group</li> <li>Advising a global charity on the VAT implications of its internal operations.</li> </ul>

<p>Adrian specialises in advising clients on all issues relating to the enforcement and validity of patents and supplementary protection certificates, including topical issues such as medical use claims, plausibility, antibody functional claims, Article 3 of the SPC Regulation, and the doctrine of equivalents. Adrian also acts for clients in contractual disputes involving patent rights, both before the High Court and in private international arbitrations.</p> <p>In addition to his expertise in English proceedings, Adrian frequently assists clients with the coordination of litigation in other jurisdictions, working with law firms in Europe, Korea, India, China and the Middle East. In particular Adrian advises a top five pharmaceutical company in the enforcement of its worldwide patent portfolio for two of its blockbuster drugs.</p> <p>Adrian’s recent experience includes:</p> <ul> <li>Actavis v Eli Lilly (atomoxetine, Patents Court)</li> <li>Warner Lambert v NHS England (pregabalin, Patents Court)</li> <li>Teva v Eli Lilly (galcanezumab, Patents Court)</li> <li>Alcon v Aspire & Accord (travoprost, Patents Court, Court of Appeal)</li> <li>Sandoz v BMS (apixaban, Patents Court, Court of Appeal)</li> <li>Celltrion v Novartis & Genentech (omalizumab, Patents Court)</li> </ul>

<p>Simon specialises in copyright and design rights, database rights, trade marks, passing off, domain names and breach of confidence.</p> <p>As a litigator he has acted for clients in the High Court, Court of Appeal, Supreme Court, Court of Justice of the EU, as well as in the Copyright Tribunal and the IP Enterprise Court, including appearing as a Solicitor Advocate.</p> <p>Simon specialises in online intellectual property issues, such as representing the NLA and six of the national newspapers in the proceedings brought against Meltwater and the PRCA on copyright in newspaper headlines, summaries and internet browsing, which went to the European Court of Justice, the Supreme Court and the Copyright Tribunal. He had advised numerous clients on the challenges brought about by AI, covering the full spectrum from content owners, intermediaries/app developers and AI businesses. He also regularly acts for computer games clients, both enforcing their rights and defending them in court proceedings.</p> <p>Simon represents clients in High Court trade mark actions and trade mark proceedings before the UKIPO, and also manages several well-known international brand portfolios. Simon sits as an Appointed Person, a judicial role hearing trade mark appeals from the UKIPO.</p> <p>He has always been particularly active in the design industry, including acting for some of the country’s leading furniture, textile, fashion and product design companies. For example, he acted for the successful defendant in the important design rights case, Neptune (Europe) Ltd v DeVol Kitchens Ltd [2017] EWHC 2172 (Pat).</p> <p>He is also a member of the Executive Committee of BLACA (the British Literary and Artistic Copyright Association), a member of INTA’s Rights of Publicity Committee and Round Tables committee, a tutor on the Oxford IP Diploma course, and the co-author of ‘Intellectual Property’, a textbook published by Palgrave MacMillan, currently in its sixth edition.</p>